False Negatives in Quick COVID-19 Test Near 15 Percent: Study

Abbott’s ID NOW test missed the most positive samples among five products given the green light by the FDA to use during the pandemic.

Written byLisa Winter
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

ABOVE: © ISTOCK.COM, SOUTH_AGENCY

As the SARS-CoV-2 pandemic continues with global cases nearing 2.5 million, clinicians have raised questions about the accuracy of available COVID-19 tests. After in-house testing of different available tests, one physician found that Abbott’s assay using its ID NOW device, which can provide results in 5–13 minutes, has a false-negative rate that nears 15 percent. The full results, first reported by NPR, have not been published or peer-reviewed.

Gary Procop is the chairman of the commission of science, technology and policy for the American Society for Clinical Pathology, and is currently heading up COVID-19 testing at Cleveland Clinic. He and his team took 239 patient samples known to be positive for the virus and re-tested them using five products available through the US Food and Drug Administration’s (FDA) emergency use authorization. The test that turned out to be the least accurate is the one known for ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Lisa joined The Scientist in 2017. As social media editor, some of her duties include creating content, managing interactions, and developing strategies for the brand’s social media presence. She also contributes to the News & Opinion section of the website. Lisa holds a degree in Biological Sciences with a concentration in genetics, cell, and developmental biology from Arizona State University and has worked in science communication since 2012.

    View Full Profile
Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies